<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375685</url>
  </required_header>
  <id_info>
    <org_study_id>CL3-78989-019</org_study_id>
    <secondary_id>2013-004973-29</secondary_id>
    <nct_id>NCT02375685</nct_id>
  </id_info>
  <brief_title>Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)</brief_title>
  <acronym>EYEGUARD-X</acronym>
  <official_title>A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate long-term safety of gevokizumab in patient with
      chronic non-infectious uveitis who previously well tolerated the study drug and may benefit
      from longterm treatment with gevokizumab.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoints (adverse events, ...)</measure>
    <time_frame>108 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Chronic Uveitis</condition>
  <arm_group>
    <arm_group_label>gevokizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gevokizumab</intervention_name>
    <arm_group_label>gevokizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  either completed participation to one of the following: CL3-78989-002 open-label
             extension, or X052130/CL3-78989-005 double-masked period or open-label period, or
             X052131/CL3-78989-006 double-masked period or open-label period, or currently
             benefiting from gevokizumab compassionate use after participation in gevokizumab
             uveitis studies

          -  Male or female, age ≥18 (or legal age of majority in the country) at selection.

          -  For subject with reproductive potential, a willingness to use highly effective
             contraceptive measures

        Exclusion Criteria:

          -  Meeting criteria for discontinuation of any of gevokizumab uveitis previous study.

          -  Infectious uveitis and masquerade syndrome

          -  History of severe allergic or anaphylactic reaction to study drug administration
             during previous study or to gevokizumab or any of its excipient.

          -  Currently active infectious disease.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Competence</name>
      <address>
        <city>Wien</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU-Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interbalkan Medical Center</name>
      <address>
        <city>Thessaloníki</city>
        <zip>57 001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIBILI</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICOF ( Institut Clinic d'Oftalmologia )</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital-Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fattouma Bourguiba University hospital</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://ghr.nlm.nih.gov/condition/behcet-disease</url>
    <description>Genetics Home Reference</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/848/behcets-disease/resources/1</url>
    <description>Behcet's Disease</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/6060/chorioretinitis/resources/1</url>
    <description>Chorioretinitis</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/8577/panuveitis/resources/1</url>
    <description>Panuveitis</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/7339/pars-planitis/resources/1</url>
    <description>Pars Planitis</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/4457/posterior-uveitis/resources/1</url>
    <description>Posterior Uveitis</description>
  </link>
  <link>
    <url>http://rarediseases.info.nih.gov/gard/8192/uveal-diseases/resources/1</url>
    <description>Uveal Diseases</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <link>
    <url>http://clinicaltrials.servier.com/wp-content/uploads/CL3-78989-019_synopsis_report.pdf</url>
    <description>Results summary</description>
  </link>
  <results_reference>
    <citation>Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O, Gül A. Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study. Ocul Immunol Inflamm. 2018 Jan 25:1-11. doi: 10.1080/09273948.2017.1421233. [Epub ahead of print]</citation>
    <PMID>29370572</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uveitis</keyword>
  <keyword>Non-infectious Uveitis</keyword>
  <keyword>Intermediate Uveitis</keyword>
  <keyword>Posterior Uveitis</keyword>
  <keyword>Behçet's disease uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

